Recovery after Covid-19

Borst, Bram van den

doi:10.1016/j.lanwpc.2021.100208

Cited by 6 publications

(4 citation statements)

References 10 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is not yet known whether breakthrough infections increase risk of “long COVID” [otherwise known as post-acute sequelae of COVID-19 (PASC)], a constellation of debilitating and lingering symptoms after infection. These symptoms can lead to physiologic disruption of multiple organ systems; substantial disruption of daily life, employment, and mental health; and a higher burden on the health care system ( 40 , 41 ). Long COVID has been observed as a consequence of both mild and severe infection ( 42 ), raising the possibility that survivors of breakthrough infections may also be at risk for long COVID.…”

mentioning

confidence: 99%

SARS-CoV-2 vaccine protection and deaths among US veterans during 2021

Cohn

Cirillo

Murphy

et al. 2022

Science

225

229

View full text Add to dashboard Cite

We report severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine effectiveness against infection (VE-I) and death (VE-D) by vaccine type in 780,225 veterans in the Veterans Health Administration, covering 2.7% of the US population. From February to October 2021, VE-I declined for all vaccine types, and the decline was greatest for the Janssen vaccine, resulting in a VE-I of 13.1%. Although breakthrough infection increased risk of death, vaccination remained protective against death in persons who became infected during the Delta variant surge. From July to October 2021, VE-D for age <65 years was 73.0% for Janssen, 81.5% for Moderna, and 84.3% for Pfizer-BioNTech; VE-D for age ≥65 years was 52.2% for Janssen, 75.5% for Moderna, and 70.1% for Pfizer-BioNTech. Findings support continued efforts to increase vaccination, booster campaigns, and multiple additional layers of protection against infection.

show abstract

mentioning

confidence: 99%

SARS-CoV-2 vaccine protection and deaths among US veterans during 2021

Cohn

Cirillo

Murphy

et al. 2022

Science

225

229

View full text Add to dashboard Cite

show abstract

“… 34–37 In an Australian study, 80, 90 and 93% recovered by 1, 2 and 3 mo, respectively. 38 On the other hand, in an Italian study of 143 hospital-discharged COVID-19 patients (at a mean of 60 d), 12.6, 32 and 55% were completely free of symptoms, had 1–2 or ≥3 symptoms, respectively. 39 None had fever or features of an acute illness, while the main manifestations were fatigue (53%), dyspnoea (43%), joint pain (27%) and chest pain (22%).…”

Section: Discussionmentioning

confidence: 97%

Postdischarge outcomes of COVID-19 patients from South Asia: a prospective study

Abeysuriya

Seneviratne

Silva

et al. 2022

Transactions of the Royal Society of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Background Coronavirus disease 2019 (COVID-19) may cause clinical manifestations that last for weeks or months after hospital discharge. The manifestations are heterogeneous and vary in their frequency. Their multisystem nature requires a holistic approach to management. There are sparse data from the South Asian region on the outcomes of hospital-discharged COVID-19 patients. We assessed the posthospital discharge outcomes of a cohort of Sri Lankan COVID-19 patients and explored the factors that influenced these outcomes. Methods Data were prospectively collected from patients who were discharged following an admission to the Nawaloka Hospital, Sri Lanka with COVID-19 from March to June 2021. At discharge, their demographic, clinical and laboratory findings were recorded. The patients were categorised as having mild, moderate and severe COVID-19, based on the Sri Lanka Ministry of Health COVID-19 guidelines. Following discharge, information on health status, complications and outcomes was collected through clinic visits and preplanned telephone interviews. A validated (in Sri Lanka) version of the Short Form 36 health survey questionnaire (SF-36) was used to assess multi-item dimensions health status of the patients at 1, 2 and 3 mo postdischarge. Results We collected data on 203 patients (male, n=111 [54.7%]). The level of vaccination was significantly associated with disease severity (p<0.001). Early recovery was seen in the mild group compared with the moderate and severe groups. At 3 mo, on average 98% of mild and 90% of moderate/severe patients had recovered. Based on the SF-36, physical functioning dimensions, role limitation due to physical and emotional health, energy/ fatigue, emotional well-being, social functioning, pain and general health were significantly different in the moderate/severe vs mild COVID-19 groups at 1, 2 and 3 mo postdischarge (p<0.05). Twenty-three patients developed complications, of which the most common were myocardial infarction with heart failure (n=6/23; 26.1%), cerebrovascular accident (n=6/23; 26.1%) and respiratory tract infections (n=3/23; 13.01%) and there were six deaths. Conclusions In our cohort, receiving two doses of the COVID-19 vaccine was associated with reduced disease severity. Those with mild disease recovered faster than those with moderate/severe disease. At 3 mo posthospital discharge, >90% had recovered.

show abstract

“…Indeed, radiological lung lesions and reduced long diffusion capacity are found in a large proportion of COVID-19 survivors, three months after contagion (Zhao et al. 2020 ; van den Borst 2021 ). However, long-COVID has been noted in patients with normal lung radiological aspect and function (Arnold et al.…”

Section: Discussionmentioning

confidence: 99%

Polysomnographic parameters in long-COVID chronic insomnia patients

Taïeb

Caetano

Pitron

et al. 2023

Dialogues in Clinical Neuroscience

View full text Add to dashboard Cite

Introduction While COVID-19 is predominantly considered to be an acute self-remitting disease, it has been pointed out that a variety of symptoms can linger for several months, a phenomenon identified as long-COVID. Insomnia is particularly prevalent in long-COVID. In the present study, we aimed at confirming and characterising insomnia in long-COVID patients through polysomnography and to identify whether its parameters differ from patients with chronic insomnia and no long-COVID history. Materials and methods We conducted a case-control study, including 17 long-COVID patients with insomnia symptoms (cases), and 34 2:1 matched controls with a diagnostic of chronic insomnia and no history of long-COVID. All underwent a one-night polysomnography (PSG). Results First, we observed that long-COVID patients with insomnia complaints have altered PSG parameters, in favour of the diagnosis of chronic insomnia. Second, we show that insomnia related to long-COVID PSG parameters was not significantly different from regular chronic insomnia PSG parameters. Discussion Our results indicate that even though it is one of the most prevalent symptoms of long-COVID, its related insomnia resembles typical chronic insomnia, based on PSG studies. Even though additional studies are warranted, our results suggest that the pathophysiology and therapeutic options should be similar to those recommended for chronic insomnia.

show abstract

Recovery after Covid-19

Cited by 6 publications

References 10 publications

SARS-CoV-2 vaccine protection and deaths among US veterans during 2021

SARS-CoV-2 vaccine protection and deaths among US veterans during 2021

Postdischarge outcomes of COVID-19 patients from South Asia: a prospective study

Polysomnographic parameters in long-COVID chronic insomnia patients

Contact Info

Product

Resources

About